CERS - Cerus Corporation
| Previous Close | 4.2000 |
| Open | 4.2200 |
| Bid | 0.0000 x 4000 |
| Ask | 0.0000 x 3100 |
| Day's Range | 4.1700 - 4.2450 |
| 52 Week Range | 3.9500 - 6.8800 |
| Volume | 419,050 |
| Avg. Volume | 876,951 |
| Market Cap | 593.932M |
| Beta (3Y Monthly) | 1.61 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5130 |
| Earnings Date | Oct 30, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.00 |
- Thomson Reuters StreetEvents
Edited Transcript of CERS earnings conference call or presentation 30-Oct-19 8:30pm GMT
Q3 2019 Cerus Corp Earnings Call
- Business Wire
Cerus Corporation to Present at the Stifel 2019 Healthcare Conference
Cerus Corporation announced today that Kevin D. Green, Cerus’ chief financial officer, will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 2:25 p.m.
- Simply Wall St.
How Should Investors React To Cerus Corporation's (NASDAQ:CERS) CEO Pay?
Obi Greenman has been the CEO of Cerus Corporation (NASDAQ:CERS) since 2011. First, this article will compare CEO...
- Business Wire
Cerus Corporation to Present at the Stephens Nashville Investment Conference
Cerus Corporation announced today that Kevin D. Green, Cerus’ chief financial officer, will present at the Stephens Nashville Investment Conference on Wednesday, November 13, 2019 at 10:30 a.m.
- Insider Monkey
Were Hedge Funds Right About Cashing Out Of Cerus Corporation (CERS)?
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of June. At Insider Monkey, we follow nearly 750 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]
- Benzinga
The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Oct. 31) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ...
- Zacks
Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates
Cerus (CERS) delivered earnings and revenue surprises of -18.18% and 2.76%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Cerus Corporation Announces Third Quarter 2019 Results
Cerus Corporation today announced financial results for the third quarter ended September 30, 2019.
- Zacks
Will Cerus (CERS) Report Negative Earnings Next Week? What You Should Know
Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire
Cerus Corporation to Release Third Quarter 2019 Results and to Discuss Recent FDA Guidance for Bacterial Safety of Platelets on October 30, 2019
Cerus Corporation announced today that its third quarter 2019 results will be released on Wednesday, October 30, 2019, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M.
- Business Wire
Cerus Corporation Announces Schedule of Presentations at the 2019 AABB Annual Meeting
Cerus Corporation announced today its schedule of key events and presentations at the 2019 AABB Annual Meeting which is taking place in San Antonio, Texas on October 19th through October 22nd.
- Simply Wall St.
How Much Are Cerus Corporation (NASDAQ:CERS) Insiders Taking Off The Table?
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
- Business Wire
Cerus Corporation Applauds the Publication of the Final Guidance Document on Bacterial Safety Standards for Platelet Collection and Transfusion
Cerus Corporation applauds the publication of the FDA final guidance document titled Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion; Guidance for Industry.
- Simply Wall St.
Did You Miss Cerus's (NASDAQ:CERS) 32% Share Price Gain?
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Better yet...
- Thomson Reuters StreetEvents
Edited Transcript of CERS earnings conference call or presentation 1-Aug-19 8:30pm GMT
Q2 2019 Cerus Corp Earnings Call
- Simply Wall St.
What Kind Of Shareholder Appears On The Cerus Corporation's (NASDAQ:CERS) Shareholder Register?
A look at the shareholders of Cerus Corporation (NASDAQ:CERS) can tell us which group is most powerful. Institutions...
Motley FoolCerus Corporation (CERS) Q2 2019 Earnings Call Transcript
CERS earnings call for the period ending June 30, 2019.
- Zacks
Cerus (CERS) Reports Q2 Loss, Tops Revenue Estimates
Cerus (CERS) delivered earnings and revenue surprises of -8.33% and 5.50%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Analysts Estimate Cerus (CERS) to Report a Decline in Earnings: What to Look Out for
Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Cerus Corporation (NASDAQ:CERS): Time For A Financial Health Check
While small-cap stocks, such as Cerus Corporation (NASDAQ:CERS) with its market cap of US$744m, are popular for their...
- Insider Monkey
Here’s What Hedge Funds Think About Cerus Corporation (CERS)
The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]
